-DOCSTART- -X- O
Antisense -X- _ O
oligonucleotides -X- _ O
( -X- _ O
AOs -X- _ O
) -X- _ O
are -X- _ O
currently -X- _ O
the -X- _ O
most -X- _ O
promising -X- _ O
therapeutic -X- _ O
intervention -X- _ O
for -X- _ O
Duchenne -X- _ B-Patient
muscular -X- _ I-Patient
dystrophy -X- _ I-Patient
( -X- _ I-Patient
DMD -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
AOs -X- _ O
modulate -X- _ O
dystrophin -X- _ O
pre-mRNA -X- _ O
splicing -X- _ O
, -X- _ O
thereby -X- _ O
specifically -X- _ O
restoring -X- _ O
the -X- _ O
dystrophin -X- _ O
reading -X- _ O
frame -X- _ O
and -X- _ O
generating -X- _ O
a -X- _ O
truncated -X- _ O
but -X- _ O
semifunctional -X- _ O
dystrophin -X- _ O
protein. -X- _ O
Challenges -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
this -X- _ O
approach -X- _ O
are -X- _ O
the -X- _ O
relatively -X- _ O
poor -X- _ O
systemic -X- _ O
AO -X- _ O
delivery -X- _ O
and -X- _ O
inefficient -X- _ O
dystrophin -X- _ O
correction -X- _ O
in -X- _ O
affected -X- _ O
non-skeletal -X- _ O
muscle -X- _ O
tissues -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
heart. -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
reported -X- _ O
impressive -X- _ O
heart -X- _ O
activity -X- _ O
including -X- _ O
high-splicing -X- _ O
efficiency -X- _ O
and -X- _ O
dystrophin -X- _ O
restoration -X- _ O
following -X- _ O
a -X- _ O
single -X- _ O
administration -X- _ O
of -X- _ O
an -X- _ O
arginine-rich -X- _ O
cell- -X- _ O
penetrating -X- _ O
peptide -X- _ O
( -X- _ O
CPPs -X- _ O
) -X- _ O
conjugated -X- _ O
to -X- _ O
a -X- _ O
phosphorodiamidate -X- _ O
morpholino -X- _ O
oligonucleotide -X- _ O
( -X- _ O
PMO -X- _ O
) -X- _ O
: -X- _ O
Pip5e-PMO. -X- _ B-Intervention
However -X- _ O
, -X- _ O
the -X- _ O
mechanisms -X- _ O
underlying -X- _ O
this -X- _ O
activity -X- _ O
are -X- _ O
poorly -X- _ O
understood. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
studies -X- _ O
involving -X- _ O
single -X- _ B-Intervention
dose -X- _ I-Intervention
administration -X- _ I-Intervention
( -X- _ I-Intervention
12.5 -X- _ I-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
derivatives -X- _ I-Intervention
of -X- _ I-Intervention
Pip5e- -X- _ I-Intervention
PMO -X- _ I-Intervention
, -X- _ O
consecutively -X- _ O
assigned -X- _ O
as -X- _ O
Pip6-PMOs. -X- _ O
These -X- _ O
peptide-PMOs -X- _ O
comprise -X- _ O
alterations -X- _ O
to -X- _ O
the -X- _ O
central -X- _ O
hydrophobic -X- _ O
core -X- _ O
of -X- _ O
the -X- _ O
Pip5e -X- _ O
peptide -X- _ O
and -X- _ O
illustrate -X- _ B-Outcome
that -X- _ I-Outcome
certain -X- _ I-Outcome
changes -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
peptide -X- _ I-Outcome
sequence -X- _ I-Outcome
improves -X- _ I-Outcome
its -X- _ I-Outcome
activity -X- _ I-Outcome
; -X- _ O
however -X- _ O
, -X- _ O
partial -X- _ O
deletions -X- _ O
within -X- _ O
the -X- _ O
hydrophobic -X- _ B-Outcome
core -X- _ I-Outcome
abolish -X- _ I-Outcome
its -X- _ I-Outcome
efficiency. -X- _ I-Outcome
Our -X- _ I-Outcome
data -X- _ I-Outcome
indicate -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
hydrophobic -X- _ I-Outcome
core -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
Pip -X- _ I-Outcome
sequences -X- _ I-Outcome
is -X- _ I-Outcome
critical -X- _ I-Outcome
for -X- _ I-Outcome
PMO -X- _ I-Outcome
delivery -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
heart -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
specific -X- _ I-Outcome
modifications -X- _ I-Outcome
to -X- _ I-Outcome
this -X- _ I-Outcome
region -X- _ I-Outcome
can -X- _ I-Outcome
enhance -X- _ I-Outcome
activity -X- _ I-Outcome
further. -X- _ I-Outcome
The -X- _ O
results -X- _ O
have -X- _ O
implications -X- _ O
for -X- _ O
therapeutic -X- _ O
PMO -X- _ O
development -X- _ O
for -X- _ O
DMD -X- _ O
. -X- _ O

